MorphoSys AG (MOR) Stock Price & Overview
NASDAQ:MOR • US6177602025
Current stock price
The current stock price of MOR is 18.96 USD. Today MOR is up by 2.43%. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.
MOR Key Statistics
- Market Cap
- 2.856B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.38
- Dividend Yield
- N/A
MOR Stock Performance
MOR Stock Chart
MOR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
MOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MOR. MOR may be in some trouble as it scores bad on both profitability and health.
MOR Earnings
On April 29, 2024 MOR reported an EPS of -2.04 and a revenue of 27.54M. The company missed EPS expectations (-115317.26% surprise) and missed revenue expectations (-49.34% surprise).
MOR Forecast & Estimates
12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96.
For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR
MOR Groups
Sector & Classification
MOR Financial Highlights
Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MOR Ownership
MOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 362.351B | ||
| AMGN | AMGEN INC | 15.35 | 188.551B | ||
| GILD | GILEAD SCIENCES INC | 15.5 | 170.497B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.17 | 114.627B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.74 | 77.866B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 40.96 | 40.669B | ||
| INSM | INSMED INC | N/A | 31.035B | ||
| NTRA | NATERA INC | N/A | 28.359B | ||
| BIIB | BIOGEN INC | 11.43 | 26.951B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.75 | 22.845B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.149B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MOR
Company Profile
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Company Info
IPO: 1999-03-09
MorphoSys AG
Semmelweisstr. 7
Planegg BAYERN 82152 DE
CEO: Jean-Paul Kress
Employees: 464
Phone: 4989899270
MorphoSys AG / MOR FAQ
What does MOR do?
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
What is the stock price of MorphoSys AG today?
The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.
Does MOR stock pay dividends?
MOR does not pay a dividend.
What is the ChartMill rating of MorphoSys AG stock?
MOR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is MOR stock listed?
MOR stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for MOR stock?
MorphoSys AG (MOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.38).